CatalystMarker
← board

AZTR

Azitra Inc.distress 7/10 · high distress / dilution risk
$0.13-2%today-92% from 52w high
azitrainc.com13 employeesFounded 2014Branford, CTBiotechnology
Lead: EGFR Inhibitor-associated Rash
Revenue
pre-revenue
Liquidity
$10M
Runway
0.9 yrs
Shares 1y
-31%

Price & events

-55.0% over 6M
$0.13$0.21$0.30Jan 26Apr 26Jul 26515.2Mdilution: EFFECT shelf_effective (2026-06-02)dilution: S-1 shelf_registration (2026-05-21)financing: 8-K private_placement (2026-03-23)catalyst: PHASE1 ATR12-351 (2026-06-01) — click to open
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
-3.8%
1W
-39.1%
1M
-40.0%
3M
-55.3%
6M
-91.9%
1Y
-99.6%
2Y
5Y
-100.0%
All

Overview

Market Cap
$2.07M
Volume
106.75K
52 Week Range
$0.13 – $1.58
Total Shares
16.19M
Float Shares
12.13M
Short %
2.63%
% Held by Insiders
28.42%
% Held by Institutions
6.27%
RVOL
0.00x
Beta
-1.21

Pipeline stages · 3 programs

ATR04-484
Preclin
Ph1
Ph2
Ph3
Filed
PDUFA
Approved
next 2027-01-15
ATR-04
Preclin
Ph1
Ph2
Ph3
Filed
PDUFA
Approved
ATR12-351
Preclin
Ph1
Ph2
Ph3
Filed
PDUFA
Approved

Pipeline · 3 trials · 1 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2027-01-15
Estimated 50%
readout ~2027-03-01
Phase 1/2ATR04-484fast trackEGFR Inhibitor-associated Rashrecruiting
2026-06-01
Phase 1ATR12-351Netherton Syndrome12recruiting
2026-01
Phase 1/2ATR-04fast trackEpidermal Growth Factor, Papulopustular Rosacea0withdrawn

Catalyst news & presentations · 4

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 16,192,438 · 2 offerings/1y · 2 PIPEs
  • 2026-06-02EFFECTshelf_effective
  • 2026-05-21S-1shelf_registration
  • 2026-03-238-Kprivate_placement
  • 2025-12-16424B3offering
  • 2025-12-15EFFECTshelf_effective
  • 2025-12-10S-1shelf_registration
  • 2025-11-258-Kprivate_placement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2025-09-24Maxim GroupBuy

Competitors — EGFR Inhibitor-associated Rash

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.